Yelda Komesli
Nowadays, the use of fluorescent labeled molecules with near infrared dye at in vivo imaging, are increasingly common in the pharmaceutical field. Although there were many studies on the imaging of the drugs after iv injection, there have been no oral biodistribution studies similar to our study. BCS Clas II type, antihypertensive drug Olmesartan medoxomil is a prodrug which is converted to olmesartan with low bioavailability in the gastrointestinal tract. The aim of this work was to prove increased oral biodistribution of Olmesartan by fluorescent labelled Self-Microemulsifying Drug Delivery System . In this study, VivoTag® 680 XL was chosen for the determination of the biodistribution of OM-SMEDDS.Labelled OM-SMEDDS and control dye administered group of mice visualised and emission values were recorded during the experiment. Preparation of OM-SMEDDS: The experiments were carried out using our previous standardized and optimized SMEDDS and validated HPLC method. The precipitated OM-SMEDDS was transferred to another epandorf and the remaining washed portion was administered with 150 μl of oral gavage to the mice .The results were statistically evaluated with one-way ANOVA (Analysis of variance) method. Differences in p values were considered significant (p<0.05.